Drew Pardoll on neoadjuvant nivolumab in stage 1-3 NSCLC

Redaktion: Dr. Gerhard Emrich

Produktion: Oliver Eberhardt


Warning: Undefined property: medonline\theme\lib\templates\MoSingle::$ID in /appl/www/htdocs/medonline/web/app/themes/mydailyapplenew/templates/entry-meta-video.php on line 56

Drew Pardoll, MD, PhD, director of Bloomberg~Kimmel Institute for Cancer Immunotherapy and director of Cancer Immunology at Johns Hopkins School talks about the data from a clinical trial in which nivolumab was given prior to resection in stage 1-3 NSCLC. According to the results, the administration of neoadjuvant nivolumab in this setting is safe and resulted in major pathological responses in 45% of the patients.